scholarly journals Immune Response to anti-HBs Antibodies in Health Workers Following Hepatitis B Vaccination

2021 ◽  
Vol 7 (2) ◽  
pp. 182
Author(s):  
Dinna Rakhmina ◽  
Wahdah Norsiah ◽  
Tini Elyn Herlina ◽  
Norhafizah Mulia Sari ◽  
Reza Pertiwi ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Antibody Response ◽  
Health Workers ◽  
Hepatitis B Surface Antigen ◽  
Strong Association ◽  
Hepatitis B Vaccination ◽  
Enzyme Linked Immunosorbent Assay ◽  
Dose Frequency ◽  
Post Vaccination

According to Regulation No. 53 of 2015 of the Minister of Health of the Republic of Indonesia, a high risk of HBV infection in health workers is a problem that requires attention, and vaccination knowledge is critical to reducing these risk factors. Furthermore, because some people do not produce a sufficient antibody-forming (anti-HBs) response to HBsAg, testing for evidence of protective immunity against hepatitis B vaccination is required (Hepatitis B Surface Antigen). The purpose of the study was to determine the mapping of the characteristics of anti-HBs antibodies response after hepatitis B vaccination in health workers in terms of age, gender, ethnicity, smoking habits, obesity, vaccination frequency, last time of vaccination. Sixty vaccinated health workers were used to creating the research sample. Anti-HBs levels/titers in serum were measured using the Enzyme-Linked Immunosorbent Assay (ELISA) method, and a questionnaire was used to compile the data for this study. Age, gender, smoking, obesity, and vaccination dose were all used to map the outcomes of the anti-HBs antibody immune response study. Anti-HBs antibody response in health workers was graded as poor in 36 people (60%) and strong in 24 (40%). Regarding ethnic origin, lifestyle, obesity, and vaccination dose (frequency), there was no significant link between post-vaccination anti-HBs antibody response in health workers. In terms of age and gender, there is a strong association between post-vaccination anti-HBs antibody responses in health workers. Low antibody titers should be revaccinated to enhance anti-HBs titers, and health workers who smoke should quit because it reduces the levels of anti-HBs titers produced clinically.

scholarly journals Altered or Impaired Immune Response to Hepatitis B Vaccine in WNIN/GR-Ob Rat: An Obese Rat Model with Impaired Glucose Tolerance

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Prathibha Bandaru ◽  
Hemalatha Rajkumar ◽  
Giridharan Nappanveettil
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Rat Model ◽  
Hepatitis B Surface Antigen ◽  
Peritoneal Macrophages ◽  
Hepatitis B Vaccination ◽  
Cell Mediated Immunity ◽  
No Production

Obesity is shown to increase the incidence and severity of infectious diseases and individuals seem to exhibit poor antibody response to vaccination due to several inherent immune defects. With the increasing prevalence of impaired glucose tolerance (IGT) seen in obese individuals, the present study was aimed to investigate the basal immune response and immune response upon Hepatitis B vaccination (HBV) in an obese rat model WNIN/GR-Ob with impaired glucose tolerance (IGT). Decreased proportions of splenic CD4+ T helper cells and CD3+ T cells were observed in obese animals compared to lean animals. Upon HBV, obese animals showed reduced cell-mediated immunity and humoral immunity in terms of splenic lymphocyte proliferative response to Concanavalin A (Con A) and Hepatitis B surface antigen (HBsAg) and HBsAg-specific IgG response. Innate immunity as assessed in terms of Tumor Necrosis Factor α (TNF α) and Nitric oxide (NO) production by peritoneal macrophages upon HBV was low and unchanged, respectively, in obese animals. Thus long-term immunological memory is impaired or altered upon HBV.

How Far we are towards Eradication of HBV Infection

2015 ◽  
Vol 24 (4) ◽  
pp. 473-479 ◽  
Author(s):  
Mihai Voiculescu
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
T Cell ◽  
Hepatitis B ◽  
T Cell Receptors ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Major Health Problem ◽  
Cell Receptors ◽  
B Virus

Hepatitis B virus (HBV) infection is a major health problem with an important biological and a significant socio-economic impact all over the world. There is a high pressure to come up with a new and more efficient strategy against HBV infection, especially after the recent success of HCV treatment. Preventing HBV infection through vaccine is currently the most efficient way to decrease HBV-related cirrhosis and liver cancer incidence, as well as the best way to suppress the HBV reservoir. The vaccine is safe and efficient in 80-95% of cases. One of its most important roles is to reduce materno-fetal transmission, by giving the first dose of vaccine in the first 24 hours after birth. Transmission of HBV infection early in life is still frequent, especially in countries with high endemicity.Successful HBV clearance by the host is immune-mediated, with a complex combined innate and adaptive cellular and humoral immune response. Different factors, such as the quantity and the sequence of HBV epitope during processing by dendritic cells and presenting by different HLA molecules or the polymorphism of T cell receptors (TOL) are part of a complex network which influences the final response. A new potential therapeutic strategy is to restore T-cell antiviral function and to improve innate and adaptive immune response by immunotherapeutic manipulation.It appears that HBV eradication is far from being completed in the next decades, and a new strategy against HBV infection must be considered. Abbreviations: ALT: alanine aminotransferase; APC: antigen presenting cells; cccDNA: covalently closed circular DNA; HBIG: hepatitis B immunoglobulin; HbsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; CTL: cytotoxic T lymphocyte; IFN: interferon; NUC: nucleos(t)ide analogues; pg RNA: pre genomic RNA; TLR: toll-like receptors; TOL: T cell receptors.

scholarly journals 1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S562-S562
Author(s):  
Robert Gish ◽  
Vincent Streva
Keyword(s):  
Hepatitis B ◽  
Immune Escape ◽  
Hepatitis B Surface Antigen ◽  
Panel Member ◽  
The United States ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Review Panel ◽  
B Virus ◽  
Escape Mutants

Abstract Background Although overall infection rates of Hepatitis B virus (HBV) in the United States (US) remain stable, as many as 2.2 million persons are still chronically infected with Hepatitis B Virus (HBV)1. Persons who inject drugs (PWID) are at a higher risk of HBV infection and since 2009 three states (KY, TN, WV) have reported up to a 114% increase in cases of acute HBV infection due to higher infection rates among a non-Hispanic white populations (30–39 years), and injection drug users2. Hepatitis B vaccination is recommended as primary prevention for adults who are at increased risk for HBV infection, including PWID. However, data from the National Health Interview Survey indicate that hepatitis B vaccination coverage is low among adults in the general population3, and it is likely to be lower among injection drug users. Hepatitis B Surface Antigen (HBsAg) is the first serological marker to appear after HBV exposure and infection; this marker is included in the recommended panel for acute hepatitis diagnosis and accurate detection is necessary for early and accurate diagnosis. Serological testing challenges exist for HBsAg due to the high degree of genetic variability which can further be exacerbated by endogenous and exogenous pressures. The immuno-dominant region may have one or more mutations described as immune escape mutations which can decrease or abrogate HBsAg binding to antibodies used in immunoassays. Although the prevalence of these mutations is not well documented in the United States, international studies have shown that up to 79% of HBV-reactivated patients (vs 3.1% of control patients; p< 0.001) carry HBsAg mutations localized in immune-active HBsAg regions4. Methods A study was conducted using a panel of 10 unique recombinant HBsAg immune escape mutants. Panel members were tested by commercially available HBsAg serological immunoassays. Results It was found that although commercially available HBsAg immunoassays are the primary diagnostic tool for HBV diagnosis, not all HBsAg immune escape mutants are detected, with some method detecting as few as 5 out of 10 of these mutant samples. Figure 1 Conclusion Improvement is needed in commercially available methods for the accurate detection of HBsAg. Disclosures Robert Gish, MD, Abbott (Consultant)AbbVie (Consultant, Advisor or Review Panel member, Speaker’s Bureau)Access Biologicals (Consultant)Antios (Consultant)Arrowhead (Consultant)Bayer (Consultant, Speaker’s Bureau)Bristol Myers (Consultant, Speaker’s Bureau)Dova (Consultant, Speaker’s Bureau)Dynavax (Consultant)Eiger (Consultant, Advisor or Review Panel member)Eisai (Consultant, Speaker’s Bureau)Enyo (Consultant)eStudySite (Consultant, Advisor or Review Panel member)Exelixis (Consultant)Fujifilm/Wako (Consultant)Genentech (Consultant)Genlantis (Consultant)Gilead (Consultant, Advisor or Review Panel member, Speaker’s Bureau)GLG (Consultant)HepaTX (Consultant, Advisor or Review Panel member)HepQuant (Consultant, Advisor or Review Panel member)Intercept (Consultant, Speaker’s Bureau)Ionis (Consultant)Janssen (Consultant)Laboratory for Advanced Medicine (Consultant)Lilly (Consultant)Merck (Consultant)Salix (Consultant, Speaker’s Bureau)Shionogi (Consultant, Speaker’s Bureau)Viking (Consultant)

scholarly journals Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles

2008 ◽  
Vol 69 (2) ◽  
pp. 405-416 ◽  
Author(s):  
Olga Borges ◽  
Anabela Cordeiro-da-Silva ◽  
Joana Tavares ◽  
Nuno Santarém ◽  
Adriano de Sousa ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Chitosan Nanoparticles ◽  
Nasal Delivery ◽  
Cpg Odn

scholarly journals Prevalence and risk factors of hepatitis b infection in HIV infected children seen at national hospital Abuja

2021 ◽  
Vol 48 (2) ◽  
pp. 62-65
Author(s):  
O.A. Adeoye ◽  
O. Oniyangi ◽  
I.A. Ojuawo
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Hepatitis B Surface Antigen ◽  
Significant Risk ◽  
Hepatitis B Vaccination ◽  
Rapid Progression ◽  
Hepatitis B Infection ◽  
National Hospital ◽  
Blood Samples ◽  
Paediatric Hiv

Background: Human immunodeficiency virus infection remains a global pandemic. Co infection with hepatitis B virus leads to rapid progression to AIDS if not diagnosed and promptly treated or better still prevented. The study aims at determining the prevalence and risk factors of hepatitis B infection in HIV infected children being followed up at the Paediatric HIV clinic. Patients and methods: A cross-sectional study of 261 HIV infected children aged eight months to fourteen years to determine the prevalence of Hepatitis B infection and pattern of hepatitis B vaccination was carried out between July and October 2012 at the Paediatric HIV clinic of National Hospital Abuja. Ethical approval was obtained from Ethical Committee of the hospital. Vaccination and transfusion history were obtained from the parents and guardians of the subjects using a proforma after signed informed consent. Blood samples were collected for Hepatitis B surface antigen screening and Hepatitis B screening in those with HBsAg positive blood samples. Results: Only 3 (1.15%) of the 261 HIV infected children had Hepatitis B infection. All the children less than 5 years old in this cohort received hepatitis B vaccination and none of them had Hepatitis B infection. The HIV/HBV co infected children were older than ten years (p = 0.047) and history of blood transfusion (p = 0.003) was also significant. However, scarification (p = 0.996), local circumcision (p = 0.928); uvulectomy (p = 0.898) were not significant risk factors in this cohort. Conclusion: There is need to intensify routine hepatitis B vaccination and routine screening of blood before necessary transfusion. This would further lead to a low prevalence of Hepatitis B in HIV infected children and the general populace at large.

scholarly journals PACKAGING OF HEPATITIS B SURFACE ANTIGEN VACCINE AND MORINGA OLEIFERA EXTRACT INTO CHITOSAN NANOPARTICLES

2019 ◽  
Vol 12 (1) ◽  
pp. 346
Author(s):  
Diky Mudhakir ◽  
Adik Ahmadi ◽  
Muhamad Insanu ◽  
Neny Nuraini
Keyword(s):  
Immune Response ◽  
Particle Size ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Moringa Oleifera ◽  
Hepatitis B Surface Antigen ◽  
Polyacrylamide Gel Electrophoresis ◽  
Sodium Dodecyl ◽  
Chitosan Nanoparticles ◽  
Entrapment Efficiency

Objective: Oftentimes, the recombinant antigen for the use of vaccines is less immunogenic than live attenuated or inactive vaccines. Hence, a potent adjuvant is needed to enhance the immune response. Moreover, the role of vector design is also important to facilitate the improvement of the immune response. The aim of this research was to develop hepatitis B surface antigen (HBsAg)-loaded nanoparticles and Moringa oleifera aqueous leaf extracts as an adjuvant using chitosan polymer. Methods: Chitosan nanoparticles were prepared by the ionic gelation method using sodium tripolyphosphate as the cross-linking agent. A system was composed of chitosan core in which HBsAg and M. oleifera extracts were incorporated. The concentration of HBsAg used in this combination was 10 μg/ml, and the concentrations of extracts were 10, 50, and 100 μg/ml, respectively. In this study, three types of nanoparticles were produced: HBsAg-loaded nanoparticles, M. oleifera-loaded nanoparticles, and combination of HBsAg–M. oleifera-loaded nanoparticles. The nanoparticles formed were characterized by the particle size, HBsAg entrapment efficiency using sodium dodecyl sulfate polyacrylamide gel electrophoresis, and the entrapment efficiency of extracts using the total flavonoid method. Results: The results showed that the particle size was between 111 and 245 nm. The entrapment efficiency of HBsAg in the separate formula was 79%, while that in the combined formula was approximately 96–98%. Furthermore, the entrapment efficiency of the extracts in the separate formula was around 64–91%, while that in the combined formula was 55–82.5%. Particularly, HBsAg–M. oleifera-loaded chitosan nanoparticles with the extract concentrations of 50 μg/ml showed the highest entrapment efficiencies of HBsAg and M. oleifera extracts of approximately 98 and 82.5%, respectively. Conclusion: Collectively, the system has been successfully developed, so it is then plausible to determine the function of the devices to enhance the immune response in the future.

scholarly journals Hepatitis B Awareness Among Medical Students And Their Vaccination Status In A Medical College In Western UP.

2019 ◽  
pp. 57-59
Author(s):  
Rajni Dawar ◽  
Tabassum Yasmin ◽  
Ajay Kumar Jha
Keyword(s):  
Medical Students ◽  
High Risk ◽  
Data Collection ◽  
Hepatitis B ◽  
Health Care Professionals ◽  
Hepatitis B Surface Antigen ◽  
Vaccination Status ◽  
Hepatitis B Vaccination ◽  
Universal Precautions ◽  
Medical College

Background: India is in the intermediate hepatitis B virus endemicity zone with hepatitis B surface antigen prevalence among the general population ranging from 2% to 8%.Health care professionals are at a high risk of getting .Hep B infection which can be prevented by strategies like vaccination, increasing awareness and following universal precautions. The present study was conducted on medical students (3rd Semester) to evaluate their knowledge regarding HBV and to know their vaccination status. Also along with data collection, students were educated about hepatitis B vaccine and about universal precautions before they start with their clinical postings. Methods: Cross sectional study was carried out on 3rd semester MBBS students (batch 2012-2013). All the students present on the day of data collection were included in the study and interviewed using pretested questionnaire. Data was analyzed using percentages. Results: Most of the students had good knowledge about disease and modes of transmission & prevention. Surprisingly only 56.6 percent were aware of high risk of transmission to health professional and doctors. Main source of information was media (85.4percent).Nearly 82% of the students were immunized and main reason among those unimmunized was unawareness about vaccine availability. Conclusions: It is recommended that Hepatitis B vaccination should be made available for all unimmunized students who enter medical profession. The orientation and sensitization programm should be held to create awareness regarding HBV infection preferably at the time of admission into medical college ,else no later than start of their clinical posting.

scholarly journals Evaluation of Anti-HBs Antibody Immune Response against Hepatitis B virus in Vaccinated People in а North-eastern Bulgaria Region

Folia Medica ◽  
2019 ◽  
Vol 61 (4) ◽  
pp. 572-578
Author(s):  
Denitsa T. Tsaneva-Damyanova ◽  
Liliya I. Ivanova ◽  
Silviya N. Pavlova ◽  
Svetlana B. Todorova ◽  
Tsvetelina K. Popova
Keyword(s):  
Immune Response ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Age Groups ◽  
University Hospital ◽  
Human Pathogens ◽  
Serum Samples ◽  
Post Vaccination ◽  
B Virus ◽  
Mass Immunization

Introduction: Hepatitis B virus (HBV) is one of the most significant human pathogens responsible for a huge number of acute and chronic liver infectious diseases worldwide. Aim: To find the duration of post-vaccination immune response in individuals allocated to five age groups from 6 months to 20 years. Materials and methods: All tested subjects were born between 1999 and 2018 and therefore covered by the compulsory vaccination program against hepatitis B. For the serological marker anti-HBs Ab we investigated 449 serum samples taken from ambulatory people and patients of St Marina University Hospital in Varna. Results: A positive antibody response (anti-HBs Ab > 10 mIU/ml) was reported in 79.7% (n = 51) of the group of subjects up to one year old, in 70.0% (n = 196) of the subjects in the age range 1 year/1 month to 15 years, and in 39.3% (n = 33) of the subjects 15 years/1 month to 20 years old. Female sex had a better post-vaccination response than male sex with statistically significant relationship between sex and anti-HBs Ab titer (&chi;2 = 24.76, p <0.01). Conclusions: Regardless of the mass immunization against HBV in Bulgaria, the relative share of chronic HBV infections does not show a downward trend. Therefore, it is very important to study the duration of the post-vaccination immune response by demonstrating the anti-HBs antibodies and to apply a booster dose from the vaccine if needed.

Sign in / Sign up

Export Citation Format

Share Document